Company Overview

Biophytis S.A. is a clinical-stage biotechnology company focused on the development of therapeutic candidates for age-related diseases, particularly conditions associated with muscle degeneration and respiratory failure. The company operates within the biotechnology and pharmaceutical research and development industries, with an emphasis on small-molecule drug candidates targeting biological pathways involved in muscle function and inflammation.

The company’s primary value driver is its lead drug candidate Sarconeos (BIO101), which has been investigated for indications including sarcopenia, respiratory complications, and severe COVID‑19–related respiratory failure. Biophytis primarily serves healthcare systems, clinicians, and aging patient populations through late-stage clinical development rather than commercialized products. Founded in France in the mid‑2000s, the company evolved from academic research into a publicly listed biotech, expanding its clinical focus and accessing international capital markets through listings in Europe and the United States.

Business Operations

Biophytis’ operations are centered on pharmaceutical research and clinical development, with no commercial manufacturing or sales as of the latest publicly available disclosures. The company operates as a single reportable segment focused on drug discovery and clinical validation, with internal expertise in preclinical research, regulatory strategy, and clinical trial management. Revenue generation to date has primarily consisted of research grants, public funding, and capital raised through equity offerings rather than product sales.

Operational activities are conducted primarily through the parent entity Biophytis S.A., with clinical trials executed via partnerships with contract research organizations and academic institutions. The company maintains a subsidiary presence in the United States through Biophytis USA Inc., supporting regulatory engagement and clinical development activities. Data inconclusive based on available public sources regarding any active joint ventures or revenue-generating partnerships.

Strategic Position & Investments

Strategically, Biophytis is positioned as a niche developer of therapies addressing unmet medical needs in aging-related diseases, a segment with long-term demographic tailwinds. Its growth strategy has focused on advancing Sarconeos (BIO101) through Phase 2 and Phase 3 clinical trials, expanding potential indications to maximize the asset’s clinical and commercial relevance.

The company has invested heavily in clinical development infrastructure and intellectual property surrounding its lead compound rather than diversifying into multiple unrelated pipelines. No material acquisitions of external companies have been consistently verified across public filings. Emerging areas of focus include inflammatory and metabolic pathways related to muscle degeneration, though additional pipeline assets beyond BIO101 remain limited based on publicly available data.

Geographic Footprint

Biophytis is headquartered in France, with its principal executive and research operations based in Paris. The company maintains an operational and regulatory presence in the United States through Biophytis USA Inc., reflecting its intention to access U.S. capital markets and conduct FDA‑regulated clinical trials.

Clinical trial activity has extended across Europe and North America, with study sites in multiple countries depending on indication and trial phase. While the company does not report material commercial operations outside these regions, its investor base and market listings provide international exposure across European and U.S. financial markets.

Leadership & Governance

Biophytis was co-founded by executives with backgrounds in pharmaceutical research and entrepreneurship, and it continues to be led by members of its founding team. The leadership emphasizes a strategy centered on scientific rigor, focused capital allocation, and advancing late-stage clinical assets in defined therapeutic areas.

Key executives include:

• Stanislas Veillet – Chief Executive Officer
• Thierry Boissel – Deputy Chief Executive Officer
• Christophe Bagnis – Chief Medical Officer
• Guillaume Le Fur – Chief Financial Officer

The governance structure follows standard European public company practices, with oversight provided by a board of directors and alignment with regulatory requirements associated with its listings on Euronext Growth Paris and U.S. over-the-counter markets under the ticker BPTSY.